Bayer SE secures rights to in €310m deal
Under the licence deal, BridgeBio Pharma, Inc. will pass the commercialisation rights for the transthyretin stabiliser acoramidis in Europe where...
Nordic Bioproducts Group opens its first production facility
Nordic Bioproduct’s commercial-scale manufacturing site is expected to create €40m in revenue in the first full operating year. In...
Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
Roche opens €90m gene therapy development centre
Roche sees the €90m investment as a harbinger of the German government's "National Strategy for Gene and Cell Therapies", which has been...
AstraZeneca to acquire Amolyt Pharma for up to US$1.05bn
Under the agreement set to close in Q3/2024, AstraZeneca will acquire Amolyt Pharma for US$800m upfront and potential milestone payments of US$250m....
Novo Nordisk to acquire Cardior Pharmaceuticals
The take-over agreement includes Cardior’s lead compound CDR132L, currently in Phase II clinical development for the treatment of heart failure....
Biovian and 3P Biopharmaceuticals join forces to create 3PBIOVIAN
Finnish Biovian Oy and Pamplona-based 3P Biopharmaceuticals Srl have joined forces to build a pan-European Contract Development and Manufacturing...